Core Viewpoint - The treatment of asthma has evolved from mere symptom control to achieving clinical cure, supported by advancements in modern medicine and the introduction of biological agents [2][3] Group 1: Asthma Treatment Insights - Asthma has the highest prevalence among chronic respiratory diseases globally, while chronic obstructive pulmonary disease (COPD) ranks first in China, with asthma in second place [2] - The clinical cure goals for asthma include four "zeros": no obvious symptoms, no asthma attacks, normal lung function, and no need for oral steroids [2] - Various biological agents such as omalizumab, mepolizumab, benralizumab, and dupilumab have shown promising clinical cure rates, providing more options for patients [2] Group 2: Challenges and Future Directions - The usage rate of biological agents in China is currently low, presenting challenges for broader adoption [2] - Long-term use of biological agents can effectively reduce acute attacks, emergency visits, and hospitalizations, making them cost-effective in overall healthcare expenditure [2] - Ongoing research is focused on developing targeted drugs for different cytokines and pathways, with new biological agents expected to enter clinical use [3] - Achieving the goal of clinical cure for asthma requires collaborative efforts from healthcare providers, patients, government, and society [3]

Group 1 - The core viewpoint of the articles emphasizes the chronic nature of asthma as an airway inflammatory disease that requires ongoing management and treatment to prevent acute attacks and long-term complications [2][4][6] - The importance of adhering to prescribed inhalation therapies, particularly the combination of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA), is highlighted as essential for controlling inflammation and alleviating symptoms [3][4] - A significant portion of asthma patients in China, approximately 55%-70%, are not effectively managing their condition, indicating a substantial unmet medical need [3] Group 2 - Severe asthma patients, constituting about 5% of the asthma population in China, face higher risks of complications and economic burdens due to frequent acute episodes and hospitalizations [5] - Innovative therapies, particularly biologics, are emerging as effective treatments for severe asthma, targeting specific inflammatory pathways and reducing reliance on corticosteroids [5][6] - The recent update to the bronchial asthma prevention and treatment guidelines introduces the concept of "clinical cure," offering hope for better management and quality of life for severe asthma patients [6]